Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

被引:100
作者
Perez-De-Lis, Marta [1 ]
Retamozo, Soledad [2 ,3 ,4 ]
Flores-Chavez, Alejandra [2 ,5 ,6 ]
Kostov, Belchin [7 ]
Perez-Alvarez, Roberto [8 ]
Brito-Zeron, Pilar [2 ,9 ]
Ramos-Casals, Manuel [2 ,10 ]
机构
[1] Complejo Hosp Univ A Coruna, Serv Anestesiol & Reanimac, La Coruna, Spain
[2] Hosp Clin Barcelona, Lab Autoimmune Dis Josep Font, IDIBAPS CELLEX, Dept Autoimmune Dis,ICMiD, Barcelona, Spain
[3] Univ Cordoba, Hosp Privado, Cordoba, Argentina
[4] Consejo Nacl Invest Cient & Tecn, Inst Invest Ciencias Salud INICSA, Cordoba, Argentina
[5] Hosp Especialidades Ctr Med La Raza, Unidad Invest Biomed 02, Unidad Invest Epidemiol Clin, CMNO,IMSS, Guadalajara, Jalisco, Mexico
[6] Univ Colima, Programa Doctorado Ciencias Med, CUIB, Colima, Mexico
[7] IDIBAPS, Primary Care Res Grp, Barcelona, Spain
[8] Hosp Alvaro Cunqueiro, Dept Internal Med, Vigo, Spain
[9] Hosp CIMA Sanitas, Autoimmune Dis Unit, Dept Med, Barcelona, Spain
[10] Univ Barcelona, Dept Med, Barcelona, Spain
关键词
Autoimmune disease; anti-TNF agents; rituximab; immune checkpoint inhibitors; growth factor inhibitors; cancer; big data; drug-induced event; NECROSIS-FACTOR-ALPHA; LATE-ONSET NEUTROPENIA; INFLAMMATORY-BOWEL-DISEASE; JUVENILE IDIOPATHIC ARTHRITIS; CELL LUNG-CANCER; ANTI-TNF THERAPY; PHASE-II TRIAL; MODIFYING ANTIRHEUMATIC DRUGS; METASTATIC COLORECTAL-CANCER; ACTIVE RHEUMATOID-ARTHRITIS;
D O I
10.1080/14740338.2017.1372421
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Biological drugs are therapies designed to target a specific molecule of the immune system that have been linked with the development of autoimmune diseases. Areas covered: The BIOGEAS Registry currently collects information about nearly 13,000 reported cases of autoimmune diseases developed in patients exposed to biologics, including more than 50 different systemic and organ-specific autoimmune disorders, of which psoriasis (n=6375), inflammatory bowel disease (n=845), demyelinating CNS disease (n=803), interstitial lung disease (n=519) and lupus (n=369) were the most frequently reported. The main biologics involved were anti-TNF agents in 9133 cases (adalimumab in 4154, infliximab in 3078 and etanercept in 1681), immune checkpoint inhibitors in 913 (ipilimumab in 524 and nivolumab in 225), B-cell targeted therapies in 741 (rituximab in 678), and growth factor inhibitors in 549 cases (bevacizumab in 544). Even though targeting a particular immune molecule may be associated with an excellent clinical response in most patients, an unexpected autoimmune disease may arise in around 8 out of 10,000 exposed patients. Expert opinion: Following the increased use of biologics, the number and diversity of induced autoimmune diseases is increasing exponentially. Management of these disorders will be an increasing clinical challenge in the daily practice in the next years.
引用
收藏
页码:1255 / 1271
页数:17
相关论文
共 245 条
[1]   Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab [J].
Abdulkader, Rita ;
Dharmapalaiah, Chethana ;
Rose, Ginny ;
Shand, Lynne M. ;
Clunie, Gavin P. ;
Watts, Richard A. .
JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) :858-861
[2]   Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation [J].
Abou-Jaoude, MM ;
Ghantous, I ;
Almawi, WY .
MOLECULAR IMMUNOLOGY, 2003, 39 (17-18) :1083-1088
[3]   The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series [J].
Afzali, Anita ;
Wheat, Chelle L. ;
Hu, Jie Kate ;
Olerud, John E. ;
Lee, Scott D. .
JOURNAL OF CROHNS & COLITIS, 2014, 8 (06) :480-488
[4]   Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma [J].
Aguiar-Bujanda, David ;
Jesus Blanco-Sanchez, Maria ;
Hernandez-Sosa, Maria ;
Galvan-Ruiz, Saray ;
Hernandez-Sarmiento, Samuel ;
Saura-Grau, Salvador ;
Bohn-Sarmiento, Uriel .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (12) :761-765
[5]   Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT [J].
Alabed, Yazan Z. ;
Aghayev, Ayaz ;
Sakellis, Christopher ;
Van den Abbeele, Annick D. .
CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) :e528-e529
[6]   Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma [J].
Albarel, Frederique ;
Gaudy, Caroline ;
Castinetti, Frederic ;
Carre, Tiphaine ;
Morange, Isabelle ;
Conte-Devolx, Bernard ;
Grob, Jean-Jacrues ;
Brue, Thierry .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :195-204
[7]   Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor [J].
Albattal, Basel M. .
ANNALS OF SAUDI MEDICINE, 2016, 36 (03) :190-196
[8]   Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].
Ansell, Stephen M. ;
Hurvitz, Sara A. ;
Koenig, Patricia A. ;
LaPlant, Betsy R. ;
Kabat, Brian F. ;
Fernando, Donna ;
Habermann, Thomas M. ;
Inwards, David J. ;
Verma, Meena ;
Yamada, Reiko ;
Erlichman, Charles ;
Lowy, Israel ;
Timmerman, John M. .
CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453
[9]   Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma [J].
Arai, Yasuyuki ;
Yamashita, Kouhei ;
Mizugishi, Kiyomi ;
Nishikori, Momoko ;
Hishizawa, Masakatsu ;
Kondo, Tadakazu ;
Kitano, Toshiyuki ;
Kawabata, Hiroshi ;
Kadowaki, Norimitsu ;
Takaori-Kondo, Akifumi .
Hematology, 2015, 20 (04) :196-202
[10]   Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine [J].
Aslanidis, Spyros ;
Pyrpasopoulou, Athina ;
Douma, Stella ;
Triantafyllou, Areti .
CLINICAL RHEUMATOLOGY, 2008, 27 (03) :377-380